COMMUNIQUÉS West-GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - March 2024
12/04/2024
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’ [...]
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Mars 2024
12/04/2024
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers Sanofi Société [...]
Nexstim Plc Resolved on a New Stock Option Plan 2024H
12/04/2024
Company Announcement, Helsinki, 12 April 2024 at 9 PM (EEST) Nexstim Plc Resolved on a New Stock Option Plan 2024H Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that the Board of Directors of Nexstim [...]
MEDIA ADVISORY: Press conferences with patients who have been charged user fees of hundreds or even thousands of dollars at for-profit surgery clinics
12/04/2024
TORONTO and LONDON and WATERLOO and BRAMPTON, Ontario, April 12, 2024 (GLOBE NEWSWIRE) -- Patients are being threatened with extremely long wait times, denied vital procedure information, and coerced or manipulated into [...]
Ontario Psychological Association Unveils New Mental Health Insights - Report
12/04/2024
TORONTO, April 12, 2024 (GLOBE NEWSWIRE) -- The Ontario Psychological Association (OPA) today released a pivotal report, “ Mental Health in Ontario: Insights from AskForHelpToday.ca ,” based on an analysis of over 12, [...]
Intermountain McKay Dee Hospital and Intermountain Medical Center Named to Fortune's 2024 Top 50 Heart Hospitals List
12/04/2024
SALT LAKE CITY and OGDEN, Utah, April 12, 2024 (GLOBE NEWSWIRE) -- Two Intermountain Health facilities have been named 2024 Top 50 Heart Hospitals in the U.S. by Fortune Magazine. Intermountain McKay-Dee Hospital in [...]
Clarification of guidance for revenue and lower than expected operating profit in the 2023/24 financial year
12/04/2024
ANNOUNCEMENT NO. 261 Clarification of guidance for revenue and lower than expected operating profit in the 2023/24 financial year According to the preliminary figures, revenue in the third quarter of 2023/24 was DKK 98. [...]
Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products
12/04/2024
Signifies the first major step towards the application process for the certification of its Mango ED oral dissolvable products by Mexico’s health governing agency, COFEPRIS Dallas, Texas, April 12, 2024 (GLOBE NEWSWIRE [...]
Teladoc Health to Announce First Quarter 2024 Financial Results
12/04/2024
PURCHASE, NY, April 12, 2024 (GLOBE NEWSWIRE) -- Teladoc Health , Inc. (NYSE: TDOC), the global leader in whole-person virtual care, announced that it will release first quarter 2024 results on Thursday, April 25, 2024 [...]
Medicare Revises 2024 Fee Schedule to Include Payment Rate for the ReWalk Personal Exoskeleton
12/04/2024
Finalized Medicare reimbursement pathway for personal exoskeletons expands access for all eligible Medicare beneficiaries MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 12, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics [...]
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives
12/04/2024
-Adenosine clinical development paused WESTPORT, Conn., April 12, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use [...]
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
12/04/2024
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple [...]
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
12/04/2024
Innovative design of ongoing Phase 3 clinical program expected to set precedent for future clinical trials in essential tremor BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX [...]
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
12/04/2024
Company will host investor call on April 17 at 8:00 a.m. ET to discuss new data from GTX-102 Phase 1/2 clinical study in patients with Angelman syndrome NOVATO, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Ultragenyx [...]
Notable Labs Reports 2023 Financial Results and Provides a Business Update
12/04/2024
FOSTER CITY, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing new cancer therapies identified by its [...]
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
12/04/2024
In a preliminary review of blinded data from the ongoing TREK-DX study, 45% (10/22) of patients achieved at least a 90% reduction in their EASI score (EASI-90) after 16 weeks. 56% (5/9) of patients with prior inadequate [...]
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
12/04/2024
MALVERN, Pa., April 12, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, [...]
Invivyd Announces CEO Transition
12/04/2024
Jeremy Gowler appointed Interim CEO WALTHAM, Mass., April 12, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious [...]
BioSenic provides further information on its restructuring plan
12/04/2024
PRESS RELEASE - PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, 12 April 2024, 12:00 CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory [...]

Pages